Outcomes of the Montana Asthma Home Visiting Program: A home-based asthma education program

FERNANDES, JESSIE; Biskupiak, William W; Brokaw, Sarah M.; Carpenedo, Dorota; Loveland, Katie; Tysk, Sonja; Vogl, Shea

doi:10.1080/02770903.2018.1426766

Cited by 7 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A standardised protocol was used to try to improve these patients' asthma control. This consisted of ensuring adherence to therapy and appropriate inhaler use, providing health education, adjusting treatment, and ruling out comorbidities [26][27][28].…”

Section: Study Population and Study Designmentioning

confidence: 99%

Real-life cost-effectiveness of benralizumab in patients with severe asthma

et al. 2021

View full text Add to dashboard Cite

Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma. Methods This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-related quality of life) between a 1-year baseline treatment and 1-year benralizumab treatment. The health economic evaluation included direct costs and incremental cost-effectiveness ratios (ICERs). Results After 1 year of treatment with benralizumab, patients with refractory eosinophilic asthma showed an improvement in all the effectiveness parameters analysed: improvement of asthma control and lung function, and decrease in the number of exacerbations, oral corticosteroid (both as corticosteroid courses and maintenance therapy), and inhaled corticosteroid use. The total annual cost per patient for the baseline and benralizumab treatment periods were €11,544 and €14,043, respectively, reflecting an increase in costs due to the price of the biological agent but a decrease in costs for the remaining parameters. The ICER was €602 per avoided exacerbation and €983.86 for every 3-point increase in the ACT score. Conclusions All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.

show abstract

Section: Study Population and Study Designmentioning

confidence: 99%

Real-life cost-effectiveness of benralizumab in patients with severe asthma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We used a standardised protocol to try to improve these patients' asthma control. This consisted of ensuring adherence to both therapy and appropriate inhaler use, providing health education, adjusting treatment, and ruling out comorbidities [34][35][36].…”

Section: Study Populationmentioning

confidence: 99%

Real-life experience with benralizumab during 6 months

et al. 2020

View full text Add to dashboard Cite

Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients. Methods This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units. Results A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7, p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7, p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75], p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0], p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1, p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12, p = 0.002). Side effects were mild and did not lead to treatment discontinuation. Conclusions This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.

show abstract

“…Fernandes et al [41] Nutrition Based Lesson Series (Body Balance Lesson Series) A nine-lesson nutrition-based lesson series, 'Body Balance: Protect Your Body from Pollution with a Healthy Lifestyle' was developed based on a needs-based assessment to enhance the understanding of environmental health and protective actions.…”

Section: Individualmentioning

confidence: 99%

Intervention studies to reduce the impact of climate change on health in rural communities in the United States: a systematic review

Smith

Mizelle

Leslie

et al. 2023

Environ. Res.: Health

View full text Add to dashboard Cite

Background: Climate change, the greatest public health threat of the 21st century, will uniquely affect rural areas that are geographically isolated and experience greater health inequities. This systematic review describes and evaluates interventions to lessen the effects of climate change on human health in the rural United States, including interventions on air pollution, vector ecology, water quality, severe weather, extreme heat, allergens, and water and food supply. Methods: Searches were constructed based on the eight domains of the Centers for Disease Control and Prevention (CDC) Framework “Impact of Climate Change on Human Health.'' Searches were conducted in EBSCO Environment Complete, EBSCO GreenFILE, Embase.com, MEDLINE via PubMed, and Web of Science. Duplicate citations were removed, abstracts were screened for initial inclusion, and full texts were screened for final inclusion. Pertinent data were extracted and synthesized across the eight domains. Article quality was assessed using the Mixed Methods Appraisal Tool. Results: Of 8,471 studies screened, 297 were identified for full text review, and a total 49 studies were included in this review. Across the domains, 34 unique interventions addressed: air pollution (n=8), changes in vector ecology (n=6), water quality (n=5), severe weather (n=3), extreme heat (n=2) increasing allergens (n=1), water and food supply (n=1), and interventions in multiple CDC domains (n=8). Participatory action research methodology was commonly used and strived to mobilize/empower communities to tackle climate change. Conclusion: Our review identified three randomized controlled trials, with two of these three published in the last five years. While original research on the impact of climate change on health has increased in the past decade, randomized control trials may not be ethical, cost effective, or feasible. There is a need for time-efficient and high-quality scholarship that investigates intervention efficacy and effectiveness for reducing health impacts of climate change upon rural populations.

show abstract

Outcomes of the Montana Asthma Home Visiting Program: A home-based asthma education program

Abstract: These findings suggest that it is feasible to implement a 12-month HV program using local public health resources in a rural area as outcomes improved over this time period.

Cited by 7 publications

References 15 publications

Real-life cost-effectiveness of benralizumab in patients with severe asthma

Real-life cost-effectiveness of benralizumab in patients with severe asthma

Real-life experience with benralizumab during 6 months

Intervention studies to reduce the impact of climate change on health in rural communities in the United States: a systematic review

Contact Info

Product

Resources

About